A Double-Blind, Oral, Placebo-Controlled, Multiple-Dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Intas Pharmaceuticals Limited

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Psychiatry and Psychology [F] - Mental Disorders [F03]

Trial duration

completed 2 Apr 2025

Decision date (initial)

2024-10-25

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

External identifiers

EU CT number

2024-511829-57-00

ClinicalTrials.gov

NCT04315792

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Safety, Therapy, Pharmacokinetic

To evaluate the efficacy and establish superiority of Endoxifen 8 mg
against placebo in the treatment of Adult Patients of Bipolar I Disorder
with Acute Mania/ Manic episodes with or without mixed features

Secondary objectives 1

1. To evaluate the safety and tolerability of the treatments among hospitalized patients with manic episodes with or without mixed features of Bipolar I disorder.

Conditions and MedDRA coding

Bipolar I Disorder

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 12

1. Male ≥18 to ≤65 years of age and postmenopausal female patients (12 months with no menses without an alternative medical cause) willing to give written informed consent along with at least one first degree relative (the legally acceptable representative [LAR]) to participate in the study before initiating any study related procedures.
2. Six months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL; OR Have had surgical bilateral oophorectomy (with or without hysterectomy) at least six months ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment if she is considered not of child-bearing potential.
3. Patients must have a diagnosis of Bipolar I Disorder and currently display acute manic episodes with or without mixed features according to DSM-5 criteria as judged by the Investigator.
4. Young Mania Rating Scale (YMRS) total score of >25 and ≥4 on two of four core items (irritability, speech, content, disruptive/aggressive behavior) at screening and at randomization (baseline). The optimal YMRS 23 severity threshold of 25 was chosen as this corresponds to a Positive Predictive Value (PPV) of 83%, signifying that 83% of patients with a baseline score ≥25 are at least “Markedly ill”.
5. Score of >4 in Severity of illness criteria of Clinical Global Impressions- bipolar disorder (CGI-BP) Scale for overall illness at screening and at randomization (baseline).
6. Ready for voluntary hospitalization (along with the accompanying LAR if required and as advised by the Investigator) for the current manic episode for a minimum of 2 days prior to randomization up to 21 days of in-patient treatment period.
7. Last intake of the medication(s) for BPD should be 2-7 days prior to randomization depending upon the individual drug’s plasma half-life.
8. Patient and / or LAR understand and agree to comply with all the study requirements.
9. Male patients of child begetting potential must be practicing, and any female partners must agree to the use of, highly effective contraception. Documentation should be provided for surgical sterilization for male patients not of child begetting potential.
10. Patient has not taken and agrees not to take any medication or therapy prohibited by the protocol (refer to listing in Section 14.7) for the entire study period.
11. Patients not having any significant diseases or clinically significant abnormal findings except BPD during screening-including medical history, physical examination, laboratory evaluations, 12-lead ECG and X-ray chest (postero-anterior view) recording, etc. which is likely to adversely affect patient's safety may impact the clinical outcome of the study by participating in the study or study objectives in the Investigator's opinion.
12. Subjects judged clinically not to be at serious suicide risk (all responses to the Baseline C-SSRS as “No”), or homicidal risk per clinical questioning.

Exclusion criteria 21

1. Newly diagnosed patients and not having any suitable treatment exposure in past for their Bipolar mood disorder.
2. > 20% improvement in YMRS total scores between screening and randomization visits.
3. Patients who meet DSM-5 criteria for any psychiatric disorder other than Bipolar I Disorder with Acute Mania Episode with or without mixed features.
4. Patients with seizure disorder.
5. Obsessive compulsive disorder or any other co-morbid Axis I anxiety disorder.
6. Patients with borderline or anti-social personality disorder of sufficient current severity to interfere with conduct of the study.
7. Patients with classical premenopausal symptoms were found at risk of developing intolerable hot flushes, irregular vaginal bleeding.
8. Use of the following medications: • Antihypertensive agents if stable dose has not been administered for at least 1 month before randomization • Antidepressants in the week (or a period of 5 half-lives of the drug) prior to randomization • Continuous daily or standing orders use of benzodiazepines during the month preceding screening (approximately 5 weeks prior to screening) • Potent cytochrome P450 (CYP) inducers and CYP2D6/CYP3A4 inhibitors 14 days prior to randomization • Depot antipsychotic medications within 1 dosing interval prior to randomization • Use of systemic estrogens 6 weeks prior to randomization • Patients currently on carbapenem agents
9. Any of the following laboratory abnormalities • Serum bilirubin ≥ 1.5 times ULN • Serum AST/ALT ≥ 2.5 times ULN • Serum TSH >10% above the ULN, regardless of treatment for hypothyroidism or hyperthyroidism • Serum triglyceride level > 2.5 times ULN
10. Patients with the following cardiac conditions are excluded: • Recent myocardial infarction (<12 months) • QTc prolongation (screening electrocardiogram with QTc >450 msec for men, QTc >470 msec for women) • History of QTc prolongation or using concomitant medications (as judged by the Investigator) which prolong QTc interval • Sustained cardiac arrhythmia or history of sustained cardiac arrhythmia • Decompensatory congestive heart failure • Complete left bundle branch block • First-degree heart block with PR interval >0.22 seconds
11. Presence of a coagulation disorder; active or past history of venous thromboembolism including deep venous thrombosis or pulmonary embolism.
12. Current prolonged immobilization.
13. History or current presence of retinal pathology including retinal vein thrombosis
14. Increased risk of stroke as per the Investigator’s discretion.
15. History of hypersensitivity or intolerance to tamoxifen or any other ingredients of the preparation.
16. Serious, unstable illnesses including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease as per history and medical examination.
17. Drug screen positive for any drug of abuse at screening, (with the exception of benzodiazepines used in therapeutic dose for management of acute mania), active substance abuse in the past 2 months or history of substance dependence (excluding nicotine and caffeine) within 3 months of screening.
18. History of breast or uterine cancer, or abnormal uterine bleeding.
19. Current leukopenia or thrombocytopenia as judged by the Investigator in the best health interest of the subject.
20. Clinically significant suicidal (subject responds “Yes” to any category for Baseline C- SSRS) or homicidal ideation per clinical questioning.
21. Participation in a clinical trial of another investigational drug within 30 days prior to screening.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Mean change from baseline to Day 21 on the YMRS Total Score.

Secondary endpoints 8

1. Percentage of patients with improvement of ≥ 50% in total YMRS from baseline.
2. Clinical Global Impression-Bipolar (CGI-BP) score at the end of study.
3. Mean change from baseline to the end of treatment (Day 21) in Montgomery-Åsberg Depression Rating Scale (MADRS) total score.
4. Improvement in Clinical Global Impression-Severity of Illness scale (CGI-S) score.
5. Columbia-Suicide Severity Rating Scale (C-SSRS) score at the end of treatment (Day 21).
6. Percentage of patients needing lorazepam/diazepam for controlling acute agitation/akathisia.
7. Percentage of patients requiring rescue medications and withdrawal from the study.
8. To evaluate trough concentrations of Endoxifen.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Placebo 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Intas Pharmaceuticals Limited

Sponsor organisation

Intas Pharmaceuticals Limited

Address

Premier House 1, Sarkhej Gandhi Nagar, Sarkhej Gandhi Nagar Highway, Thaltej Road Sarkhej Gandhi Nagar Sarkhej Gandhi Nagar Highway

City

Ahmedabad

Postcode

380054

Country

India

Scientific contact point

Organisation

Intas Pharmaceuticals Limited

Contact name

Vidhi Parekh

Public contact point

Organisation

Intas Pharmaceuticals Limited

Contact name

Hiralal Sonawane

Third parties 7

Locations

1 EU/EEA country · 3 investigational sites

By country

Investigational sites

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Summary of results Art. 37(4) CTR

Layperson summary Annex V

Documents 25 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

2 submissions — initial application plus substantial / non-substantial modifications